Skip to main content
    B

    BridgeBio Pharma Inc (BBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $77.36
    -0.94 (-1.20%)

    Market Cap: $15.25B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    BridgeBio Pharma Inc (BBIO) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, BridgeBio Pharma reported EPS of -$0.42, above the -$0.60 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    30%(9/30)
    Avg Surprise
    -8.99%
    Streak
    1 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.62
    Range-$0.85 - -$0.17
    22 analysts
    Revenue Consensus
    $306.94M
    Range$267.83M - $334.57M
    20 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.37
    Range-$0.62 - -$0.15
    4 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.11-224.4%
    60d ago-$0.36-2.1%
    30d ago-$0.36-2.1%
    7d ago-$0.34-9.1%
    Current-$0.37
    Revenue Consensus
    $338.05M
    Range$323.00M - $350.80M
    9 analysts

    Next Report

    BBIO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    BBIO Earnings Call

    The latest BBIO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, BBIO beat 9 and missed 21. Revenue for the quarter ended Sep 30, 2026 was $353.17M, up 192.6% from $120.70M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.42-$0.60-$0.66 - -$0.40+30.00%BeatN/A61 up, 0 downOct 29, 2026$353.17M
    Jun 30, 2026-$0.78-$0.64-$0.79 - -$0.42-21.88%MissN/A72 up, 1 downAug 10, 2026$243.68M
    Mar 31, 2026-$0.84-$0.62-$0.72 - -$0.52-35.48%MissN/A31 up, 0 downMay 7, 2026$194.51M
    Dec 31, 2025-$0.94-$0.72-$0.80 - -$0.51-31.13%MissN/A31 up, 0 downFeb 24, 2026$154.18M
    Sep 30, 2025-$0.72-$0.78-$1.01 - -$0.45+7.69%BeatN/A30 up, 3 downOct 29, 2025$120.70M
    Jun 30, 2025-$0.95-$0.60-$0.71 - -$0.50-58.33%MissN/A20 up, 0 downAug 5, 2025$110.56M
    Mar 31, 2025-$0.99-$0.89-$1.26 - -$0.76-11.10%MissN/A40 up, 1 downApr 29, 2025$116.63M
    Dec 31, 2024-$1.37-$1.09-$1.09 - -$1.09-26.09%MissN/A10 up, 1 downFeb 20, 2025$3.71M
    Sep 30, 2024-$0.86-$0.98-$1.13 - -$0.33+12.29%BeatN/A140 up, 0 downNov 12, 2024$2.73M
    Jun 30, 2024-$1.01-$0.94-$1.27 - -$0.82-7.45%MissN/A110 up, 0 downAug 1, 2024$4.34M
    Mar 31, 2024-$0.12-$0.54N/A+77.78%BeatN/A80 up, 0 downMay 2, 2024$211.12M
    Dec 31, 2023-$0.96-$0.91-$1.16 - -$0.72-5.49%MissN/A111 up, 0 downFeb 22, 2024$1.75M
    Sep 30, 2023-$1.08-$0.89-$1.00 - -$0.63-21.35%MissN/A81 up, 0 downNov 2, 2023$4.09M
    Jun 30, 2023-$0.96-$0.87-$0.94 - -$0.69-10.34%MissN/A90 up, 0 downAug 3, 2023$1.64M
    Mar 31, 2023-$0.90-$0.83-$0.91 - -$0.68-8.43%MissN/A90 up, 0 downMay 4, 2023$1.83M
    Dec 31, 2022-$0.92-$0.85-$1.14 - -$0.71-8.24%MissN/A91 up, 0 downFeb 23, 2023$1.87M
    Sep 30, 2022-$0.89-$1.01-$1.15 - -$0.89+11.88%BeatN/A70 up, 2 downNov 3, 2022$338000
    Jun 30, 2022-$0.75-$0.86-$1.12 - $0.37+12.79%BeatN/A70 up, 0 downAug 4, 2022$73.75M
    Mar 31, 2022-$1.19-$1.10-$1.18 - -$1.00-8.18%MissN/A91 up, 0 downMay 5, 2022$1.69M
    Dec 31, 2021-$1.01-$0.87-$1.15 - -$0.35-16.09%MissN/A91 up, 0 downFeb 24, 2022$12.89M
    Sep 30, 2021-$1.06-$0.91-$1.10 - -$0.67-16.48%MissN/A9N/ANov 4, 2021$2.34M
    Jun 30, 2021-$0.66-$0.89-$1.32 - -$0.34+25.84%BeatN/A7N/AAug 5, 2021$54.02M
    Mar 31, 2021-$1.18-$0.75-$1.05 - -$0.22-57.33%MissN/A8N/AMay 6, 2021$462000
    Dec 31, 2020-$1.01-$0.85-$1.05 - -$0.58-18.82%MissN/A9N/AFeb 25, 2021$122000
    Sep 30, 2020-$0.98-$0.89-$1.06 - -$0.44-10.11%MissN/A10N/ANov 5, 2020$8.13M
    Jun 30, 2020-$1.03-$0.73-$0.90 - -$0.49-41.10%MissN/A10N/AAug 11, 2020N/A
    Mar 31, 2020-$0.78-$0.70-$0.86 - -$0.51-11.43%MissN/A7N/AMay 13, 2020N/A
    Dec 31, 2019-$0.62-$0.70-$0.90 - -$0.59+11.43%BeatN/A7N/AMar 2, 2020$13.82M
    Sep 30, 2019-$0.51-$0.54-$0.58 - -$0.52+5.56%BeatN/A6N/ANov 7, 2019$26.74M
    Jun 30, 2019-$0.56-$0.40-$0.65 - -$0.30-40.00%MissN/A7N/AAug 14, 2019N/A
    Mar 31, 2019-$3.25N/AN/AN/AN/AN/AN/AN/AJun 28, 2019N/A
    Last 31 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.60, after -$3.36 the year before. It was -$4.94 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.60N/A
    Dec 31, 2024-$3.36N/A
    Dec 31, 2023-$3.90N/A
    Dec 31, 2022-$3.75N/A
    Dec 31, 2021-$3.91N/A
    Dec 31, 2020-$3.80N/A
    Dec 31, 2019-$4.94N/A

    Earnings Calls

    The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 9,300 words across 21 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20269,25421
    2026Q2Jun 30, 20268,99919
    2026Q1Mar 31, 20268,05719
    2025Q4Dec 31, 20257,96213
    2025Q3Sep 30, 20257,72017
    2025Q2Jun 30, 20258,29717
    2025Q1Mar 31, 20257,39011

    2026Q3 Earnings Call

    Opening remarks

    Chinmay Shukla Chief Business Officer Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Third Quarter 2026 Earnings Call. I am Chinmay Shukla, Chief Business Officer. With me today are Neil Kumar, our CEO; Matthew Outten, our Chief Commercial Officer; and Thomas Trimarchi, our President and Chief Financial Officer. During today's call, we will cover another quarter of consistent growth for Attruby, along with new real-world evidence that continues to differentiate acoramidis from tafamidis on outcomes that matter to patients, physicians and payers. We will then turn to BBP-418, where we are weeks away from potential launch. Finally, we will discuss the pipeline, where the PDUFA date for infigratinib is now set for February 4 with priority review and the PDUFA date for encaleret is May 8 with priority review. We're also particularly excited to discuss updates from our chronic hypoparathyroidism program, where we dosed the first patient in our Phase III trial. Following our prepared remarks, we will open the call for questions. For the Q&A session, we will be joined by the leaders of our encaleret, BBP-418 and infigratinib programs. With that, I'll turn it over to Neil.

    Neil Kumar CEO Thanks, Chinmay, and thanks, everyone, for joining today. As always, these calls are where we communicate relevant aspects of our business to investors, and so we welcome your questions and feedback. I'm excited to report updates from our TTR franchise and across the portfolio today as we enter into a new phase in our TTR launch paired with three launches ahead of us in the next seven months. I will talk about that and further contextualize the numbers from this quarter in a moment. Before I do, I want to acknowledge that we are now annualizing to over $1 billion in the U.S. market and well over that globally with our Attruby/BEYONTTRA franchise. This puts us ahead of the analogs we studied and used to guide our performance. This is coupled with an ever-leveling playing field in the United States, a consequence of Attruby's growing size, its increasing evidentiary base and the changing reimbursement environment, which we believe sets us up well in the quarters and years to come. It's interesting to remark that BEYONTTRA is the leading brand in Europe, where rules around reimbursement and marketing are tighter. For today, we feel good about our continued revenue growth. We will have to wait for Pfizer's numbers later to accurately understand our share trajectory, but numbers from our other competitor this morning show that we are solidly in second place with respect to new patient starts, and overwhelmingly so in the critical first-line setting.

    Frequently Asked Questions About BBIO

    Did BBIO beat earnings estimates last quarter?

    Yes. BridgeBio Pharma reported EPS of -$0.42 for the quarter ended Sep 30, 2026, above the -$0.60 estimate, a 30.00% surprise.

    What EPS do analysts expect from BBIO next quarter?

    The consensus EPS estimate for BridgeBio Pharma for the quarter ending Dec 31, 2026 is -$0.62 from 22 analysts, with estimates from -$0.85 to -$0.17.

    How often does BBIO beat earnings estimates?

    BridgeBio Pharma beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -18.29%.